A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Summary

This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.

Timeline

Start

2025-08-22

Primary completion

2027-12

Completion

2032-06

Drugs

Indications